These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38854928)

  • 41. The role of abuse-deterrent formulations in countering opioid misuse and abuse.
    Nguyen V; Raffa RB; Taylor R; Pergolizzi JV
    J Clin Pharm Ther; 2015 Dec; 40(6):629-34. PubMed ID: 26595258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
    Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
    Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.
    Cicero TJ; Ellis MS; Kasper ZA
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):56-62. PubMed ID: 27594167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidimensional opioid abuse deterrence using a nanoparticle-polymer hybrid formulation.
    Gad SF; Vasiukhina A; Keller JS; Solorio L; Yeo Y
    J Control Release; 2024 Jun; 370():490-500. PubMed ID: 38685384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018.
    DiPrete BL; Dasgupta N; Oh GY; Moga DC; Slavova S; Slade E; Delcher C; Pence BW; Ranapurwala SI
    Am J Epidemiol; 2024 Aug; ():. PubMed ID: 39122991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk based in vitro performance assessment of extended release abuse deterrent formulations.
    Xu X; Gupta A; Al-Ghabeish M; Calderon SN; Khan MA
    Int J Pharm; 2016 Mar; 500(1-2):255-67. PubMed ID: 26784976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.
    Peacock A; Larance B; Bruno R; Pearson SA; Buckley NA; Farrell M; Degenhardt L
    Addiction; 2019 Mar; 114(3):389-399. PubMed ID: 29989247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
    Vadivelu N; Schermer E; Kodumudi G; Berger JM
    CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
    Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
    Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
    PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.
    Webster LR; Viscusi ER; Brown C; Dayno JM
    Curr Med Res Opin; 2018 May; 34(5):893-901. PubMed ID: 29368961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
    Stanos SP; Bruckenthal P; Barkin RL
    Mayo Clin Proc; 2012 Jul; 87(7):683-94. PubMed ID: 22766088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine.
    Rossiter LF; Kwong WJ; Marrett E
    Clinicoecon Outcomes Res; 2020; 12():35-44. PubMed ID: 32021338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.